This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Idera Pharmaceuticals, Inc.
Drug Names(s): HYB2055, IMO-2055, EMD 1201081
Description: IMOxine is a Toll-like Receptor 9 (TLR9) agonist based on Idera's proprietary Immune Modulatory Oligonucleotide (IMO) technology.
Deal Structure: In December 2007, Idera Pharmaceuticals announced that it has entered into a worldwide licensing and collaboration agreement with Merck KGaA for the research, development and commercialization of Idera's Toll-like Receptor 9 (TLR9) agonists for the treatment of cancer. Under the agreement, Idera has agreed to exclusively license the therapeutic oncology applications, excluding cancer vaccines, of IMO-2055 and IMO-2125. In addition, Idera and Merck KGaA have agreed to engage in a research collaboration to identify a specified number of novel, follow-on TLR9 agonists, which will be derived using Idera's chemistry-based approach and for which Merck will have the exclusive right to use in oncology applications other than cancer vaccines. Under the terms of the agreement, Merck KGaA has agreed to pay an upfront license fee of $40 million to Idera. In addition, Idera is eligible to receive milestone payments of up to $381 million, based on current exchange rates, depending on success in...See full deal structure in Biomedtracker
Partners: Epigenesis Pharmaceuticals, Inc. Merck KGaA
Additional information available to subscribers only: